As of April 1, 2022, Independence added new preferred products for pegfilgrastim and rituximab.
Bevacizumab (marketed as Avastin®)* | - Mvasi™ (bevacizumab-awwb)
- Zirabev® (bevacizumab-bvzr)
|
Pegfilgrastim (marketed as Neulasta®) | - Fulphila® (pegfilgrastim-jmdb)
- Neulasta® (pegfilgrastim)
- Ziextenzo® (pegfilgrastim-bmez) NEW!
|
Rituximab (marketed as Rituxan®)† | - Riabni™ (rituximab-arrx) NEW!
- Ruxience™ (rituximab-pvvr)
|
Trastuzumab (marketed as Herceptin®) | - Kanjinti™ (trastuzumab-anns)
- Trazimera™ (trastuzumab-qyyp)
|
*Bevacizumab will continue to be covered for ophthalmologic indications, without precertification approval, for all branded products (e.g., Avastin, Mvasi, Zirabev).
†Rituximab preferred products apply to all oncology and non-oncology indications.
To learn more about these changes and how they affect your patients, please read our announcement article.